Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

NCT02565576 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenia Gravis, Generalized

Interventions

DRUG: Placebo
DRUG: CFZ533

Sponsor

Novartis Pharmaceuticals